Compare CECO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | TNGX |
|---|---|---|
| Founded | 1966 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.5B |
| IPO Year | 2002 | 2020 |
| Metric | CECO | TNGX |
|---|---|---|
| Price | $71.52 | $23.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $80.25 | $21.78 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 280.56 | 26.89 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $24.84 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $42.78 | $6.25 |
| 52 Week High | $101.24 | $34.39 |
| Indicator | CECO | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 35.64 |
| Support Level | $58.67 | $19.74 |
| Resistance Level | $91.13 | $25.76 |
| Average True Range (ATR) | 4.85 | 1.47 |
| MACD | 0.60 | -0.33 |
| Stochastic Oscillator | 30.50 | 8.23 |
CECO Environmental Corp is an industrial company, serving industrial air, industrial water, and energy transition markets. It offers various engineered and configured products and solutions, including dampers and diverters, selective catalytic reduction systems, severe-service and industrial cyclones, dust collectors, thermal oxidizers, filtration systems, wet and dry scrubbers, water treatment packages, industrial silencers, etc. These products are offered through brands like Western Airducts, WK, Wakefield Acoustics, Transcend, Verantis, and others. The company's reportable segments are: Engineered Systems, which derive maximum revenue, and Industrial Process Solutions. Geographically, it derives key revenue from the U.S., followed by the Netherlands, the UK, China, and other markets.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.